Obseva Logo highresolution.jpg
ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix for the Treatment of Uterine Fibroids at ASRM 2021 Scientific Congress & Expo
October 20, 2021 01:00 ET | ObsEva SA
-Final results from pilot study of linzagolix for the treatment of severe adenomyosis to be presented in a second poster -   Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss...
Obseva Logo highresolution.jpg
ObsEva Announces Presentation of Clinical Data on Oral GnRH Antagonist Linzagolix at ASRM 2021 Scientific Congress & Expo
October 19, 2021 01:00 ET | ObsEva SA
–Presentation of Phase 3 clinical data on linzagolix for the treatment of uterine fibroids and final results from a pilot study of linzagolix for the treatment of severe adenomyosis– GENEVA,...
Obseva Logo highresolution.jpg
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
October 13, 2021 01:00 ET | ObsEva SA
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix -Linzagolix, an oral GnRH antagonist, is pending regulatory approval in the U.S. and Europe for the treatment of...